Clinical significance of bone alkaline phosphatase isoforms, including the novel B1x isoform, in mild to moderate chronic kidney disease

Nephrology Dialysis Transplantation

Volumn 24, Issue 11, 2009, Pages 3382-3389

  Haarhaus, Mathias ^a,b   Fernström, Anders ^a   Magnusson, Martin ^a   Magnusson, Per ^b  

^a LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^b LINKÖPING UNIVERSITY   (Sweden)

Author keywords

Alkaline phosphatase; Bone mineral density; Bone turnover; Mineral bone disorder; Predialysis

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME 5B; ALKALINE PHOSPHATASE BONE ISOENZYME; ALKALINE PHOSPHATASE BONE ISOENZYME B1X; CALCIUM; CARBOXY TERMINAL TELOPEPTIDE; COLLAGEN; PHOSPHATE; PROCOLLAGEN TYPE 1 AMINOPROPEPTIDE; UNCLASSIFIED DRUG; ALKALINE PHOSPHATASE; ISOENZYME; PARATHYROID HORMONE;

ADULT; AGED; ARTICLE; BLOOD VESSEL CALCIFICATION; BONE DENSITY; BONE TURNOVER; CALCIUM BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DIALYSIS; DISEASE SEVERITY; ENZYME BLOOD LEVEL; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; MALE; OSSIFICATION; OSTEOLYSIS; OSTEOPENIA; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; RISK FACTOR; BLOOD; BONE; BONE REMODELING; CHRONIC DISEASE; ENZYMOLOGY; KIDNEY DISEASE; METABOLISM; MIDDLE AGED; REGRESSION ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; ALKALINE PHOSPHATASE; BONE AND BONES; BONE DENSITY; BONE REMODELING; CHRONIC DISEASE; FEMALE; HUMANS; ISOENZYMES; KIDNEY DISEASES; MALE; MIDDLE AGED; PARATHYROID HORMONE; REGRESSION ANALYSIS;

EID: 73949157189     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfp300     Document Type: Article

References (51)

1. Ho LT, Sprague SM. Renal osteodystrophy in chronic renal failure. Semin Nephrol 2002; 22: 488-493
2. Coen G, Mazzaferro S, Ballanti P, et al. Renal bone disease in 76 patients with varying degrees of predialysis chronic renal failure: a cross-sectional study. Nephrol Dial Transplant 1996; 11: 813-819
3. Ballanti P, Coen G, Mazzaferro S, et al. Histomorphometric assessment of bone turnover in uraemic patients: comparison between activation frequency and bone formation rate. Histopathology 2001; 38: 571-583
4. Leinau L, Perazella MA. Hip fractures in end-stage renal disease patients: incidence, risk factors, and prevention. Semin Dial 2006; 19: 75-79
5. London GM, Marty C, Marchais SJ, et al. Arterial calcifications and bone histomorphometry in end-stage renal disease. J Am Soc Nephrol 2004; 15: 1943-1951
6. Piraino B, Chen T, Cooperstein L, et al. Fractures and vertebral bone mineral density in patients with renal osteodystrophy. Clin Nephrol 1988; 30: 57-62
7. Coen G. Adynamic bone disease: an update and overview. J Nephrol 2005; 18: 117-122
8. Spasovski GB. Bone biopsy in the diagnosis of renal osteodystrophy. Prilozi 2004; 25: 83-93
9. Ferreira MA. Diagnosis of renal osteodystrophy: when and how to use biochemical markers and non-invasive methods; when bone biopsy is needed. Nephrol Dial Transplant 2000; 15(Suppl 5): 8-14
10. Bervoets AR, Spasovski GB, Behets GJ, et al. Useful biochemical markers for diagnosing renal osteodystrophy in predialysis end-stage renal failure patients. Am J Kidney Dis 2003; 41: 997-1007
11. Alvarez L, Torregrosa JV, Peris P, et al. Effect of hemodialysis and renal failure on serum biochemical markers of bone turnover. J Bone Miner Metab 2004; 22: 254-259
12. Obatake N, Ishimura E, Tsuchida T, et al. Annual change in bone mineral density in predialysis patients with chronic renal failure: significance of a decrease in serum 1, 25-dihydroxy-vitamin D. J Bone Miner Metab 2007; 25: 74-79
13. Tsuchida T, Ishimura E, Miki T, et al. The clinical significance of serum osteocalcin and N-terminal propeptide of type I collagen in predialysis patients with chronic renal failure. Osteoporos Int 2005; 16: 172-179
14. Urena P, De Vernejoul MC. Circulating biochemical markers of bone remodeling in uremic patients. Kidney Int 1999; 55: 2141-2156
15. Rix M, Andreassen H, Eskildsen P, et al. Bone mineral density and biochemical markers of bone turnover in patients with predialysis chronic renal failure. Kidney Int 1999; 56: 1084-1093
16. Moe S, Drueke T, Cunningham J, et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2006; 69: 1945-1953
17. Wennberg C, Hessle L, Lundberg P, et al. Functional characterization of osteoblasts and osteoclasts from alkaline phosphatase knockout mice. J Bone Miner Res 2000; 15: 1879-1888
18. Whyte MP. Hypophosphatasia and the role of alkaline phosphatase in skel, et al mineralization. Endocr Rev 1994; 15: 439-461
19. Magnusson P, Löfman O, Larsson L. Determination of alkaline phos-phatase isoenzymes in serum by high-performance liquid chromatog-raphy with post-column reaction detection. J Chromatogr 1992; 576: 79-86
20. Magnusson P, Häger A, Larsson L. Serum osteocalcin and bone and liver alkaline phosphatase isoforms in healthy children and adolescents. Pediatr Res 1995; 38: 955-961
21. Magnusson P, Degerblad M, Sääf M, et al. Different responses of bone alkaline phosphatase isoforms during recombinant insulin-like growth factor-I (IGF-I) and during growth hormone therapy in adults with growth hormone deficiency. J Bone Miner Res 1997; 12: 210-220
22. Magnusson P, Larsson L, Englund G, et al. Differencesofbone alkaline phosphatase isoforms in metastatic bone disease and discrepant effects of clodronate on different skel, et al sites indicated by the location of pain. Clin Chem 1998; 44: 1621-1628
23. Magnusson P, Sharp CA, Farley JR. Different distributions of human bone alkaline phosphatase isoforms in serum and bone tissue extracts. Clin Chim Acta 2002; 325: 59-70
24. Magnusson P, Sharp CA, Magnusson M, et al. Effect of chronic renal failure on bone turnover and bone alkaline phosphatase isoforms. Kidney Int 2001; 60: 257-265
25. Swolin-Eide D, Hansson S, Larsson L, et al. The novel bone alkaline phosphatase B1x isoform in children with kidney disease. Pediatr Nephrol 2006; 21: 1723-1729
26. Kaji H, Suzuki M, Yano S, et al. Risk factors for hip fracture in hemodialysis patients. Am J Nephrol 2002; 22: 325-331
27. Taal MW, Roe S, Masud T, et al. Total hip bone mass predicts survival in chronic hemodialysis patients. Kidney Int 2003; 63: 1116-1120
28. Mussolino ME, Madans JH, Gillum RF. Bone mineral density and mortality in women and men: the NHANES I epidemiologic follow-up study. Ann Epidemiol 2003; 13: 692-697
29. Negri AL, Barone R, Quiroga MA, et al. Bone mineral density: serum markers of bone turnover and their relationships in peritoneal dialysis. Perit Dial Int 2004; 24: 163-168
30. Hampson G, Vaja S, Evans C, et al. Comparison of the humoral markers of bone turnover and bone mineral densityin patientsonhaemodialysis and continuous ambulatory peritoneal dialysis. Nephron 2002; 91: 94-102
31. K/DOQI. Clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39: S1-S266
32. Nussbaum SR, Zahradnik RJ, Lavigne JR, et al. Highly sensitive two-site immunoradiometric assay of parathyrin, and its clinical utility in evaluating patients with hypercalcemia. Clin Chem 1987; 33: 1364-1367
33. Inaba M, Nakatsuka K, Imanishi Y, et al. Technical and clinical characterization of the Bio-PTH (1-84) immunochemiluminometric assay and comparison with a second-generation assay for parathyroid hormone. Clin Chem 2004; 50: 385-390
34. Glendenning P, Nobel PM, Taranto M, et al. Issues of methodology, standardization and metabolite recognition for 25-hydroxyvitamin D when comparing the DiaSorin radioimmunoassay and the Nichols Advantage automated chemiluminescence protein-binding assay in hip fracture cases. Ann Clin Biochem 2003; 40: 546-551
35. Rogowski O, Vered Y, Shapira I, et al. Introducing the wide range C-reactive protein (wr-CRP) into clinical use for the detection of microinflammation. Clin Chim Acta 2005; 358: 151-158
36. Melkko J, Kauppila S, Niemi S, et al. Immunoassay for intact amino-terminal propeptide of human type I procollagen. Clin Chem 1996; 42: 947-954
37. Rosenquist C, Fledelius C, Christgau S, et al. Serum CrossLaps One Step ELISA. First application of monoclonal antibodies for measurement in serum of bone-related degradation products from C-terminal telopeptides of type Icollagen. Clin Chem 1998; 44: 2281-2289
38. Sassi ML, Eriksen H, Risteli L, et al. Immunochemical characterization of assay for carboxyterminal telopeptide of human type I collagen: loss of antigenicity by treatment with cathepsin K. Bone 2000; 26: 367-373
39. Halleen JM, Alatalo SL, Suominen H, et al. Tartrate-resistant acid phosphatase 5b: a novel serum marker of bone resorption. J Bone Miner Res 2000; 15: 1337-1345
40. Sharp CA, Linder C, Magnusson P. Analysis of human bone alkaline phosphatase isoforms: comparison of isoelectric focusing and ion-exchange high-performance liquid chromatography. Clin Chim Acta 2007; 379: 105-112
41. Magnusson P, Löfman O, Larsson L. Methodological aspects on separation and reaction conditions of bone and liver alkaline phosphatase isoform analysis by high-performance liquid chromatography. Anal Biochem 1993; 211: 156-163
42. Kanis JA. Diagnosis of osteoporosis and assessment of fracture risk. Lancet 2002; 359: 1929-1936
43. Schoppet M, Shroff RC, Hofbauer LC, et al. Exploring the biology of vascular calcification in chronic kidney disease: what's circulating? Kidney Int 2008; 73: 384-390
44. Block GA, Klassen PS, Lazarus JM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004; 15: 2208-2218
45. Jono S, Shioi A, Ikari Y, et al. Vascular calcification in chronic kidney disease. J Bone Miner Metab 2006; 24: 176-181
46. Narisawa S, Harmey D, Yadav MC, et al. Novel inhibitors of alkaline phosphatase suppress vascular smooth muscle cell calcification. J Bone Miner Res 2007; 22: 1700-1710
47. Kalantar-Zadeh K, Kuwae N, Regidor DL, et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodial-ysis patients. Kidney Int 2006; 70: 771-780
48. Magnusson P, Larsson L, Magnusson M, et al. Isoforms of bone alkaline phosphatase: characterization and origin in human trabecular and cortical bone. J Bone Miner Res 1999; 14: 1926-1933
49. Lobao R, Carvalho AB, Cuppari L, et al. High prevalence of low bone mineral density in pre-dialysis chronic kidney disease patients: bone histomorphometric analysis. Clin Nephrol 2004; 62: 432-439
50. Farrugia W, Melick RA. Metabolism of osteocalcin. Calcif Tissue Int 1986; 39: 234-238
51. Magnusson P, Ä rlestig L, Paus E, et al. Monoclonal antibodies against tissue-nonspecific alkaline phosphatase. Report of the ISOBM TD9 workshop. Tumour Biol 2002; 23: 228-248